Ketogenic Diets May Increase Cancer Risk in the Small Intestine, Shifting Blame from Ketones to Dietary Fat
A groundbreaking study published this month in the esteemed journal Nature has delivered a significant re-evaluation of the widely popular ketogenic diet, particularly concerning its potential impact on cancer development. Contrary to years of prevailing scientific thought, which posited that ketone bodies—specifically beta-hydroxybutyrate (BHB)—were the primary drivers of any purported cancer-protective effects of the keto diet, new findings from researchers at the Massachusetts Institute of Technology (MIT) suggest these molecules may be mere bystanders. The study strongly indicates that dietary fat itself is the principal culprit behind increased tumor growth in the small intestine under ketogenic conditions.
This research arrives at a critical juncture, as millions globally adhere to high-fat, low-carbohydrate dietary regimens for a spectrum of health objectives, including weight management, blood sugar control, and even as a potential adjunct therapy for certain cancers. The prevailing narrative in cancer research had largely trended optimistically regarding the ketogenic diet’s potential benefits, making these new findings particularly consequential. The study, titled "Ketogenic diet mediates intestinal tumorigenesis through lipids not ketones," challenges the established understanding of how the ketogenic diet interacts with cellular metabolism and its implications for gastrointestinal health.
The Genesis of the Ketogenic Diet and the Shifting Paradigm
The ketogenic diet, originally developed in the 1920s by Dr. Russell Wilder at the Mayo Clinic, was initially conceived as a therapeutic intervention for epilepsy, particularly in children who did not respond to medication. The dietary composition is characterized by a very high percentage of fat (typically 70-80% of daily calories), a low percentage of carbohydrates (usually under 50 grams per day), and a normal or slightly reduced amount of protein. This drastic macronutrient shift forces the body into a metabolic state known as ketosis, where it primarily burns fatty acids for energy instead of glucose. The breakdown of these fatty acids results in the production of ketone bodies—acetoacetate, beta-hydroxybutyrate (BHB), and acetone—as metabolic byproducts. For decades, these ketones have been considered the key bioactive compounds responsible for many of the diet’s observed benefits, including its antiepileptic effects and, more recently, its proposed anti-cancer properties.
However, the MIT study directly questions the extent to which ketone bodies deserve credit for these effects. By meticulously dissecting the metabolic pathways involved, the researchers have pinpointed dietary fat metabolism as the more significant factor in tumor promotion within the small intestine, a finding that directly contradicts the long-held focus on ketones.
Unpacking the MIT Study: Design, Revelations, and Paradoxical Outcomes
The MIT research team embarked on a carefully designed study to investigate the potential of ketogenic diets to offer protective effects in the small intestine, mirroring promising findings previously reported for the colon. They utilized genetically engineered mice predisposed to developing intestinal cancer, a model that closely mimics certain human hereditary cancer syndromes. These mice were divided into three dietary groups: one fed a strict ketogenic diet, another a standard control diet, and a third a high-fat, high-calorie diet designed to induce obesity.
The results were striking and, for the researchers, largely unexpected. Mice on the ketogenic diet exhibited a significantly higher incidence of small intestinal tumors compared to those on the control diet. Crucially, these mice on the ketogenic diet did not become obese. Despite maintaining lean body weight—a factor typically associated with a reduced cancer risk—their tumor development rates were comparable to, or even surpassed, those of mice on the obesogenic high-fat, high-calorie diet. This observation alone presented a significant divergence from anticipated outcomes, suggesting that factors beyond caloric excess were at play.
Further investigations delved into the specific molecular mechanisms driving these tumor developments. The researchers systematically manipulated ketone production in their mouse models. They found that neither increasing nor eliminating ketone production had any discernible impact on the growth of intestinal tumors. This finding directly challenged the long-standing hypothesis that ketone bodies were the key players. Instead, the experiments revealed that the tumor-promoting effects observed in the small intestine were driven by the metabolism of dietary fat itself, rather than by the accumulation of ketone bodies.
The study also uncovered a genuinely paradoxical biological response within the gastrointestinal tract. While the ketogenic diet promoted tumor development in the small intestine, it exerted the opposite effect in the colon. Similar to findings from a 2022 study, the MIT researchers observed that a ketogenic diet suppressed the development of colon tumors in their mouse models. This stark contrast—the same diet yielding opposite outcomes in adjacent sections of the same digestive system—underscores the complex and tissue-specific nature of dietary interventions.
Omer Yilmaz, PhD, a leading figure in the study and Director of the MIT Stem Cell Initiative, articulated the core implication of these findings: "Ketogenic diets have distinct effects on different tissues even within the gastrointestinal tract. I think the message here is that we need to be very careful in generalizing the effects that these diets can have, because what might be beneficial for one tissue may be detrimental for another tissue."
Dr. Yilmaz further elaborated on the unexpected role of dietary fat: "Given how much attention has been paid to ketone bodies like BHB, both as a commercial health trend and in recent high-profile studies suggesting BHB suppresses colon cancer, we fully expected them to be the direct drivers. Instead, our experiments in genetically engineered mice revealed that these molecules are essentially metabolic bystanders. The real surprise is that tumor acceleration is driven entirely by how stem cells process and burn the heavy influx of dietary fat itself."
The mechanistic pathway elucidated by the researchers involves the process of fatty acid oxidation, a metabolic pathway by which intestinal cells break down dietary fat for energy. This process activates a family of proteins known as peroxisome proliferator-activated receptors (PPARs). These PPARs, in turn, signal intestinal stem cells to multiply at an accelerated rate. While this heightened stem cell proliferation can be advantageous for tissue repair following injury or illness, an excessive and sustained increase in stem cell numbers can tip the balance towards uncontrolled growth, thereby increasing the risk of cellular transformation into cancerous cells.
Fangtao Chi, a molecular biologist at MIT and co-first author of the study, explicitly stated the mechanistic distinction: "Neither increasing nor eliminating ketone production altered intestinal tumor growth. Instead, we found that its tumor-promoting effects in the small intestine were driven by the metabolism of dietary fat rather than by ketone bodies." The Nature paper provides molecular details, noting that combined intestinal loss of PPARα/γ/δ attenuates ketogenic diet-driven intestinal stem cell expansion, proliferation, and clonogenicity. Furthermore, inhibition of downstream fatty acid oxidation through CPT1A loss specifically limits adenoma formation under these dietary conditions, solidifying fat metabolism as the causal driver.
The Preceding Landscape: Keto and Colon Cancer Research
These new MIT findings do not emerge in a scientific vacuum. The research team was directly building upon, and in some ways recontextualizing, prior work. A significant 2022 study, also published in Nature, had presented a starkly different picture regarding the ketogenic diet and cancer. That earlier research, conducted by scientists at the University of Pennsylvania, suggested that ketogenic diets offered a protective effect against colorectal cancer, with BHB being identified as the key mediator of this benefit.
The 2022 study proposed a specific mechanism: BHB was shown to act through the surface receptor HCAR2, stimulating the transcriptional regulator HOPX. This interaction was found to alter gene expression and inhibit cell proliferation within colonic tissue. The current MIT study does not invalidate these findings concerning colon cancer protection; rather, it reframes them. While the protective effect in the colon appears to persist, the MIT research suggests that ketone bodies are not the agents responsible for this benefit. Instead, both the protective effect in the colon and the tumor-promoting effect in the small intestine now seem to be mediated through pathways related to fat metabolism, rather than ketone production. This distinction has profound implications for how the purported cancer-related claims of the ketogenic diet are interpreted by both researchers and the public.
A Genuinely Paradoxical Biology: Tissue Specificity in Focus
The most scientifically arresting aspect of the MIT findings is the pronounced tissue specificity observed. Two adjacent sections of the same digestive tract, subjected to the identical diet and metabolic state within the same animal, yielded diametrically opposed tumor outcomes. The ketogenic diet, therefore, does not exert a uniform effect across the entire gastrointestinal tract. While the colon demonstrated a reduction in tumor development, the small intestine, conversely, showed an increased susceptibility to tumor formation in mice genetically predisposed to cancer.
Dr. Yilmaz acknowledged this as a critical area for ongoing investigation, stating, "The team is now trying to understand why the same diet has such different effects in two neighboring parts of the intestine. ‘We don’t know why they’re responding differently,’ said Yilmaz. ‘That’s the question we’re working on next.’"
The direct applicability of these findings to humans remains an open question, requiring further research. The experiments were conducted in a mouse model specifically engineered to develop intestinal tumors, a condition that closely mirrors human hereditary syndromes such as familial adenomatous polyposis (FAP). FAP is a rare inherited disorder that significantly elevates an individual’s risk of developing intestinal tumors, particularly in the small intestine. The researchers emphasize that extensive human trials are necessary to confirm whether the same mechanisms operate in human populations.
An important clarification stemming from the study is the role of ketone supplements. Because the observed effects—both the tumor acceleration in the small intestine and the protection in the colon—are attributed to the metabolism of dietary fat rather than the ketones themselves, commercial ketone supplements or beverages are unlikely to replicate the biological risks or benefits identified in this research. This is particularly relevant given the observed rise in small intestinal tumors in recent decades, which has disproportionately affected individuals with inherited conditions predisposing them to intestinal cancer.
The Broader Context: Established Applications of the Ketogenic Diet
It is crucial to note that these new findings do not negate the established clinical applications and benefits of the ketogenic diet in other contexts. The diet has a century-long track record of success in managing epilepsy, a fact highlighted in a 2025 article in Nutrients. Furthermore, a robust body of evidence supports its metabolic efficacy. A 2020 meta-analysis published in Nutrients, reviewing 14 randomized controlled trials, concluded that ketogenic diets can effectively support weight loss and improve blood sugar control, particularly in individuals with obesity and type 2 diabetes, when compared to lower-fat diets.
Research into the ketogenic diet’s potential role in neurodegenerative diseases, such as Alzheimer’s, is also actively progressing. A 2025 study in Communications Medicine indicated that consuming a modified Mediterranean ketogenic diet could reverse peripheral lipid signatures associated with Alzheimer’s disease, suggesting a metabolic influence on neurodegeneration. Another 2025 study in Frontiers in Aging Neuroscience explored the interaction between the APOE4 gene variant—a significant genetic risk factor for Alzheimer’s—and the ketogenic diet. This research found that mice carrying the APOE4 variant exhibited improved memory when on a ketogenic diet compared to those on high-carbohydrate diets.
These established applications, typically pursued under medical supervision and within specific patient populations, represent a different category of use compared to the widespread consumer adoption of keto for general wellness or perceived cancer prevention. The MIT findings do not diminish the evidence supporting the ketogenic diet for epilepsy or its metabolic benefits. However, they do unequivocally signal that the diet’s effects on cancer are far more nuanced, tissue-specific, and mechanism-dependent than previously understood.
The Bottom Line: Precision and Personalized Considerations
The practical implications of this groundbreaking research are multifaceted and depend significantly on individual circumstances. For the generally healthy adult following a ketogenic diet for weight loss or blood sugar management, the MIT study, as it stands, does not establish a direct human cancer risk. The experiments were conducted in a specific mouse model with a genetic predisposition to intestinal cancer. Translating these findings to humans without such a predisposition necessitates further human clinical trials, which have not yet been conducted. The MIT research team has been explicit on this point, emphasizing that more work is required before any definitive clinical recommendations can be made.
However, for individuals diagnosed with familial adenomatous polyposis (FAP) or other hereditary conditions that significantly elevate their risk of intestinal cancer, these findings serve as a direct and urgent signal. Such individuals should engage in a thorough discussion with a medical specialist regarding any high-fat dietary approaches, including the ketogenic diet, before proceeding. The potential impact of ketogenic diets on intestinal cancer risk is of particular concern for FAP patients, who already face a substantially elevated risk of developing small intestinal tumors. This conversation is critical and should not be deferred pending further human trial data.
Furthermore, the study provides significant clarification on widely misunderstood commercial claims surrounding ketone supplements. Because the tumor-promoting effects were definitively linked to the metabolism of dietary fat rather than the ketones themselves, simply elevating ketone levels through supplementation is unlikely to confer the same biological impact—either positive or negative. Ketone drinks and BHB supplements, often marketed as a shortcut to the purported benefits of the ketogenic diet, are therefore unlikely to replicate the complex biological processes described in this research.
The overarching message from the MIT study is one of metabolic precision. It underscores that dietary lipid content, acting through fatty acid oxidation and not ketone metabolism, influences intestinal cancer development in ways that vary significantly by tissue type. The effects of a diet on the colon cannot be reliably extrapolated to its effects on the small intestine. The research cautions against interpreting any single dietary approach as uniformly safe or beneficial across all bodily systems. For anyone considering or currently following a ketogenic diet, the evolving scientific landscape now demands a more specific and personalized inquiry: "Which tissues, which genes, and which underlying health conditions apply to me?" This nuanced approach is essential for navigating the complex interplay between diet, metabolism, and cancer risk.
